“Functional” tumor treatment response parameters have been developed to measure
treatment induced biochemical changes in the entire tumor mass, using positron emission …

Unlike β particle–emitting isotopes, α emitters can selectively kill individual cancer cells with
a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically …

This review discusses the application of alpha particle-emitting radionuclides in targeted
radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, …

This trial was an initial assessment of the feasibility, in vivo targeting, and biokinetics of 16β-
18 F-fluoro-5α-dihydrotestosterone ( 18 F-FDHT) PET in patients with metastatic prostate …

Progressive dedifferentiation of thyroid cancer cells leads to a loss of iodine-concentrating
ability, with resultant false negative, whole body radioactive iodine scans in approximately 20…

A novel α-particle emitting monoclonal antibody construct targeting the external domain of
prostate-specific membrane antigen (PSMA) was prepared and evaluated in vitro and in vivo. …

PURPOSE To define the toxicity, imaging, and biodistribution characteristics of iodine 131-labeled
monoclonal antibody F19 (131I-mAbF19). MAbF19 recognizes the fibroblast …

Prolonged clearance kinetics have hampered the development of intact antibodies as
imaging agents, despite their ability to effectively deliver radionuclides to tumor targets in vivo. …

Data from nine patients with leukemia participating in a phase I activity-escalation study of
HuM195, labeled with the a-particle emitter 213Bi (half-life= 45.6 min), were used to estimate …

Results: Radiolabelingefficiencyof the CHX-A-DTPA-HuM195 construct with 213Biwas 78%
±10%(n= 46) after 10 min at specific activities of up to 1110MBq/mg. The immunoreactivity …